CTLA4 Blockade Induces Frequent Tumor Infiltration by Activated Lymphocytes Regardless of Clinical Responses in Humans von RONG RONG HUANG, JALIL, Jason, GLASPY, John A, COCHRAN, Alistair J, RIBAS, Antoni, ECONOMOU, James S, CHMIELOWSKI, Bartosz, KOYA, Richard C, MOK, Stephen, SAZEGAR, Hooman, SEJA, Elizabeth, VILLANUEVA, Arturo, GOMEZ-NAVARRO, Jesus

Volltext

Combination therapy with vemurafenib (PLX4032/RG7204) and metformin in melanoma cell lines with distinct driver mutations von Niehr, Franziska, von Euw, Erika, Attar, Narsis, Guo, Deliang, Matsunaga, Doug, Sazegar, Hooman, Ng, Charles, Glaspy, John A, Recio, Juan A, Lo, Roger S, Mischel, Paul S, Comin-Anduix, Begonya, Ribas, Antoni

Volltext

Natural killer T cells in advanced melanoma patients treated with tremelimumab von Ibarrondo, F Javier, Yang, Otto O, Chodon, Thinle, Avramis, Earl, Lee, Yohan, Sazegar, Hooman, Jalil, Jason, Chmielowski, Bartosz, Koya, Richard C, Schmid, Ingrid, Gomez-Navarro, Jesus, Jamieson, Beth D, Ribas, Antoni, Comin-Anduix, Begoña

Volltext

Modulation of cell signaling networks after CTLA4 blockade in patients with metastatic melanoma von Comin-Anduix, Begoña, Sazegar, Hooman, Chodon, Thinle, Matsunaga, Douglas, Jalil, Jason, von Euw, Erika, Escuin-Ordinas, Helena, Balderas, Robert, Chmielowski, Bartosz, Gomez-Navarro, Jesus, Koya, Richard C, Ribas, Antoni

Volltext

The Oncogenic BRAF Kinase Inhibitor PLX4032/RG7204 Does Not Affect the Viability or Function of Human Lymphocytes across a Wide Range of Concentrations von COMIN-ANDUIX, Begoña, CHODON, Thinle, SAZEGAR, Hooman, MATSUNAGA, Douglas, MOCK, Stephen, JALIL, Jason, ESCUIN-ORDINAS, Helena, CHMIELOWSKI, Bartosz, KOYA, Richard C, RIBAS, Antoni

Volltext

Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032 von Søndergaard, Jonas N, Nazarian, Ramin, Wang, Qi, Guo, Deliang, Hsueh, Teli, Mok, Stephen, Sazegar, Hooman, MacConaill, Laura E, Barretina, Jordi G, Kehoe, Sarah M, Attar, Narsis, von Euw, Erika, Zuckerman, Jonathan E, Chmielowski, Bartosz, Comin-Anduix, Begoña, Koya, Richard C, Mischel, Paul S, Lo, Roger S, Ribas, Antoni

Volltext

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation von Nazarian, Ramin, Shi, Hubing, Wang, Qi, Kong, Xiangju, Koya, Richard C., Lee, Hane, Chen, Zugen, Lee, Mi-Kyung, Attar, Narsis, Sazegar, Hooman, Chodon, Thinle, Nelson, Stanley F., McArthur, Grant, Sosman, Jeffrey A., Ribas, Antoni, Lo, Roger S.

Volltext

Abstract 5518: Characterization of invariant natural killer T cells in patients with advanced melanoma treated with CTLA4 blockade and dendritic cell vaccination von Ibarrondo, Javier, Comin-Anduix, Begoña -., Lee, Yohan, Chodon, Thinle, Sazegar, Hooman, Jalil, Jason, Chmielowski, Bartosz, Koya, Richard C., Gomez-Navarro, Jesus, Jamieson, Beth D., Ribas, Antoni

Volltext

Natural Killer T Cells in Advanced Melanoma Patients Treated with Tremelimumab: e76829 von Ibarrondo, F Javier, Yang, Otto O, Chodon, Thinle, Avramis, Earl, Lee, Yohan, Sazegar, Hooman, Jalil, Jason, Chmielowski, Bartosz, Koya, Richard C, Schmid, Ingrid

Volltext

Differential sensitivity of melanoma cell lines with BRAF .sup. V600E .sup.mutation to the specific Raf inhibitor PLX4032 von Søndergaard, Jonas N, Nazarian, Ramin, Wang, Qi, Guo, Deliang, Hsueh, Teli, Mok, Stephen, Sazegar, Hooman, MacConaill, Laura E, Barretina, Jordi G, Kehoe, Sarah M, Attar, Narsis, von Euw, Erika, Zuckerman, Jonathan E, Chmielowski, Bartosz, Comin-Anduix, Begoña, Koya, Richard C, Mischel, Paul S, Lo, Roger S, Ribas, Antoni

Volltext

Differential sensitivity of melanoma cell lines with BRAF V600E mutation to the specific Raf inhibitor PLX4032 von Søndergaard, Jonas N, Nazarian, Ramin, Wang, Qi, Guo, Deliang, Hsueh, Teli, Mok, Stephen, Sazegar, Hooman, MacConaill, Laura E, Barretina, Jordi G, Kehoe, Sarah M, Attar, Narsis, von Euw, Erika, Zuckerman, Jonathan E, Chmielowski, Bartosz, Comin-Anduix, Begoña, Koya, Richard C, Mischel, Paul S, Lo, Roger S, Ribas, Antoni

Volltext

Differential Sensitivity of Melanoma Cell Lines with BRAFV600E Mutation to the Specific Raf Inhibitor PLX4032 von Søndergaard, Jonas N, Nazarian, Ramin, Guo, Deliang, Hsueh, Teli, Mok, Stephen, Sazegar, Hooman, Barretina, Jordi G, Kehoe, Sarah M, Attar, Narsis, von Euw, Erika, Zuckerman, Jonathan E, Chmielowski, Bartosz, Comin-Anduix, Begoña, Koya, Richard C, Mischel, Paul S, Lo, Roger S, Ribas, Antoni, Wang, Qi, MacConaill, Laura Eleanor

Volltext

Combination therapy with vemurafenib and metformin in melanoma cell lines with distinct driver mutations von Niehr, Franziska, von Euw, Erika, Attar, Narsis, Guo, Deliang, Matsunaga, Doug, Sazegar, Hooman, Ng, Charles, Glaspy, John A, Recio, Juan A, Lo, Roger S, Mischel, Paul S, Comin-Anduix, Begonya, Ribas, Antoni

Volltext

Differential sensitivity of melanoma cell lines with BRAF .sup. V600E .sup.mutation to the specific Raf inhibitor PLX4032 von Søndergaard, Jonas N, Nazarian, Ramin, Wang, Qi, Guo, Deliang, Hsueh, Teli, Mok, Stephen, Sazegar, Hooman, MacConaill, Laura E, Barretina, Jordi G, Kehoe, Sarah M, Attar, Narsis, von Euw, Erika, Zuckerman, Jonathan E, Chmielowski, Bartosz, Comin-Anduix, Begoña, Koya, Richard C, Mischel, Paul S, Lo, Roger S, Ribas, Antoni

Volltext